The DC receptor DNGR-1 mediates cross-priming of CTLs during vaccinia virus infection in mice (original) (raw)
DNGR-1–deficient DCs show normal activation but reduced cross-presenting ability upon exposure to VACV-infected cells. DNGR-1 deficiency impairs the ability of DCs to stimulate the proliferation and effector differentiation of CD8+ T cells in response to antigens borne by uninfected dead cells (24). To determine whether the same is true in an infectious situation, we used a model of VACV infection. We compared Flt3L bone marrow–derived DCs (Flt3L BMDCs; a source of CD8α+-like DCs) from WT mice (H-2b) and DNGR-1–deficient (Clec9agfp/gfp) mice (24). As an antigen source, we used VACV-infected RAW macrophages (H-2d) (RAW-VACV), which can transmit virus to DCs, resulting in infection of the latter and direct antigen presentation by H-2b MHC class I molecules but can also serve as a source of cell-associated antigen for cross-presentation. Alternatively, we treated infected RAW cells with UV (RAW-VACV-UV) to inactivate the virus, blocking direct infection of DCs and leaving available only the cross-presentation route. As a control for antigen specificity, we used uninfected RAW cells treated with UV (RAW-UV). Flt3L BMDCs from WT or Clec9agfp/gfp mice were exposed to VACV-infected or control cells and used to stimulate CD8+ T cells purified from immune WT mice (previously infected with VACV) (Figure 1A). When RAW-VACV cells were used as the virus source, production of IFN-γ by vaccinia-specific effector CD8+ T cells was unaffected by loss of DNGR-1 (Figure 1, B and C). In contrast, when RAW-VACV-UV cells were used, antigen-specific CD8+ T cell stimulation was markedly reduced in the absence of DNGR-1 (Figure 1, B and C). The same result was observed with total DCs obtained from mouse LNs or with purified CD8α+ DCs from mouse spleen, indicating that it was not restricted to the use of Flt3L BMDCs (Supplemental Figure 1; supplemental material available online with this article; doi:10.1172/JCI60660DS1).
Lack of DNGR-1 blocks cross-presentation of vaccinia antigens in infected cells. (A–C) Production of IFN-γ by VACV-specific CD8+ effector T cells in response to cross-presented vaccinia antigens is severely impaired by the absence of DNGR-1 in Flt3L BMDCs. (A) For antigen presentation, RAW cells were either UV irradiated without infection (RAW-UV), infected with VACV without UV irradiation (RAW-VACV) to allow both direct presentation (DP) and cross-presentation (XP), or infected and subsequently irradiated to inactivate the virus (RAW-VACV-UV) to allow only cross-presentation. After 16 hours, RAW cells were exposed to Flt3L BMDCs from WT or Clec9agfp/gfp mice. As a readout of the restimulation ability of DCs, IFN-γ production was measured in CD8+ T cells from lymphoid organs of WT mice i.d. injected with WR VACV. (B) Representative set of dot plots. (C) Production of IFN-γ (mean ± SEM) from a representative experiment (n = 3 biological replicates) of 3 performed. **P < 0.01, #P < 0.001, unpaired 2-tailed Student’s t test.
The use of preactivated CD8+ T cells as a readout in these assays made it unlikely that the observed effect was due to an impairment of DC activation. Nevertheless, because DNGR-1 has been reported to act as a myeloid activating receptor (22), we tested whether its absence affected activation of DCs in response to RAW-VACV or RAW-VACV-UV cells. Independent of UV irradiation, VACV-infected cells induced strong DC activation, measured at the level of either costimulatory molecule upregulation (CD40, CD86) or cytokine production (TNF-α, IL-12p40). Notably, this activation was not affected by DNGR-1 deficiency (Figure 2, A and B, and Supplemental Figure 2). Moreover, lack of DNGR-1 had no effect on the expression of MHC class I (Supplemental Figure 2). These results suggest that DNGR-1, rather than determining DC activation by dead cells, regulates a non-redundant step in cross-presentation by CD8α+-like DCs of pathogen antigens associated with dead cells.
DNGR-1 does not affect DC activation in response to vaccinia-infected cells. Flt3L BMDCs from WT or Clec9agfp/gfp mice were untreated (control) or exposed for 20 hours to RAW-VACV or RAW-VACV-UV. (A) Induction of co-stimulatory molecules in DCs upon exposure to VACV-infected cells is not affected by the absence of DNGR-1. A representative set of histogram overlays is shown for CD40 (left) and CD86 (right). (B) Cytokine production induced in DCs by vaccinia-infected cells is not affected by the absence of DNGR-1. Data shown are from a representative experiment of 3 performed and are presented as mean ± SEM (n = 3 biological replicates). Differences were not statistically significant.
Dying VACV-infected cells expose DNGR-1 ligands. We next analyzed whether DNGR-1 ligands were exposed during VACV infection. Time-course analysis showed that infection of EL-4 cells with the WR VACV strain in vitro exposed the ligand in cells expressing VACV proteins as early as 24 hours after infection (Figure 3A and data not shown). All ligand-expressing cells were positive for annexin V and permeable to Hoechst 33258 staining, with a proportion of mid-positive Hoechst 33258 cells that corresponded to the transition of late apoptotic to early necrotic cells and bright positive Hoechst 33258 cells that were fully necrotic (Figure 3A).
Cells infected with vaccinia virus expose DNGR-1 ligand in vitro and in vivo. (A) Infection with VACV in vitro exposes DNGR-1 ligand. EL-4 cells were infected with WR VACV for 48 hours and stained with anti-vaccinia antibody and with control (Dectin-1–Fc) or DNGR-1–Fc constructs to detect the ligand and counterstained with annexin V and Hoechst 33258 (5 μg/ml). (B) Infection of C57BL/6 mice with VACV exposes DNGR-1 ligand simultaneously with vaccinia antigens in infected ear cells. WR VACV was injected i.d. in the ear, and, after 5 days, dermal cell suspensions were prepared as indicated in Methods. Staining and data are displayed as in A. (C) DNGR-1 is expressed in DCs locally in the ear. Cell suspensions from the ears of WT or Clec9agfp/gfp mice were semi-purified for CD11c+ cells by positive selection and stained for CD11c, CD24, and DNGR-1. A subset of CD11c+CD24hi DCs expresses DNGR-1. The dot plots in all panels are a replicate set of 3 from a representative experiment of 3 performed.
To extend these findings in vivo, we injected WR VACV i.d. into mouse ears and analyzed the presence of DNGR-1 ligand in ear cell suspensions 4 days later. A fraction of the cells from infected mice stained positive for both DNGR-1 ligand and vaccinia proteins, revealing that some infected cells expose the ligand in vivo (Figure 3B). All DNGR-1 ligand–positive cells were stained with annexin V and permeable to Hoechst 33258 — in this case the predominant fraction was cells that stained positive for Hoechst at intermediate levels (early necrotic), as the late necrotic cells had probably been removed in vivo.
VACV-infected dying cells bearing exposed DNGR-1 ligands could potentially be encountered by dermal DCs. Our analysis of DNGR-1 expression in ear cell suspensions detected a subset of CD11c+CD24hi dermal DCs that expressed DNGR-1 (Figure 3C). Cells in this subset were related to the CD8α+ DCs in lymphoid tissues and, like these cells, had an elevated capacity to cross-present exogenous antigens to CD8+ T cells (19, 21, 33).
DNGR-1 is crucial for cross-presentation of VACV antigens in vivo. To determine the contribution of DNGR-1 to cross-presentation of viral antigens in vivo, we used an established model in which mice are injected i.p. with RAW-VACV-UV cells, so that the generated CD8+ T cell response depends only on cross-presentation of VACV antigens (34). After 6 days, we restimulated effector peritoneal CD8+ T cells with MHC class I–restricted epitopes derived from the early VACV protein B8R or the late protein A3L (35) (Figure 4A). Notably, we found that DNGR-1 deficiency greatly reduced the effector CD8+ T cell response in this model (Figure 4, B and C).
Lack of DNGR-1 blocks cross-presentation of VACV antigens in vivo. (A) RAW cells were infected with WR VACV and UV treated to inactivate the virus (RAW-VACV-UV) and then transferred i.p. (107 cells per mouse) to WT and Clec9agfp/gfp mice. (B and C) Absence of DNGR-1 impairs the CD8+ effector T cell response to cross-presented VACV peptides. After 6 days, peritoneal cells were extracted and restimulated with B8R or A3L VACV peptides. (B) Representative dot plot set. (C) Absolute numbers of IFN-γ–producing CD8+ T cells found in peritoneal washes, shown as individual data from a representative experiment (n = 4 biological replicates) of 3 performed. (D and E) Lack of DNGR-1 reduces CTL killing activity in vivo against cross-presented vaccinia peptides. On day 5 after transfer, splenocytes from syngeneic mice were loaded with the early peptide B8R or the late peptide A3L (CFSElo or CellTrace_Violet_lo, respectively) or no peptide (CFSEhi or CellTrace_Violet_hi) and transferred i.p. The peritoneal lavage was analyzed 16 hours later for specific killing of targets. (D) Representative histogram set. Control histograms from noninfected mice show the proportion of transferred targets. (E) Percentage specific killing in a representative experiment of 3 performed. Data are presented as mean ± SEM (n = 4 biological replicates). **P < 0.01, #P < 0.001, unpaired 2-tailed Student’s t test.
To confirm that the ex vivo restimulated effector CD8+ T cell responses reflected systemic CTL activity in vivo, we performed an in vivo cytotoxicity assay in which the targets were syngeneic splenocytes pulsed with the specific VACV peptides and labeled with different doses of CellTrace_Violet_ or CFSE to allow discrimination by flow cytometry. Mice were injected with the targets on day 5 after primary i.p. challenge with the RAW-VACV-UV cells (Figure 4A). Analysis of killing activity in vivo 16 hours after transfer of the targets confirmed the impairment of CTL activity toward both VACV peptides (Figure 4, D and E). Thus, DNGR-1 deficiency impairs CTL activity in response to cross-presented VACV antigens.
High DNGR-1 expression is tightly restricted to CD8α+-like DCs. To unequivocally determine whether the deficiency in the CTL response was due to lack of DNGR-1 expression on CD8α+ DCs, we carried out adoptive transfer experiments using CD8α+ spleen DCs from WT or DNGR-1–deficient (Clec9agfp/gfp) mice. After incubation of splenocytes for 2 hours with RAW-VACV-UV cells, the CD8α+ spleen DCs were purified and transferred adoptively into Clec9agfp/gfp recipient mice (Figure 5A). After 7 days, ex vivo restimulation of splenocytes with B8R or A3L VACV peptides demonstrated that WT, but not DNGR-1–deficient, CD8α+ DCs efficiently transferred the ability to cross-present VACV antigens to CD8+ T cells (Figure 5B). These results were confirmed by measurement of systemic CTL activity 6 days after transfer of CD8α+ DCs (Figure 5, C and D). These data show that lack of DNGR-1 expression in CD8α+ DCs was responsible for the observed defective cross-presentation of VACV-derived antigens in vivo.
DNGR-1 expression on transferred CD8α+ spleen DCs is crucial for their ability to cross-present VACV antigens. (A) Splenocytes from WT or Clec9agfp/gfp mice were extracted and cultured for 2 hours with RAW cells infected with WR VACV and irradiated with UV to inactivate the virus (RAW-VACV-UV). CD8α+ DCs were purified as indicated in Methods and transferred into the hind paws of Clec9agfp/gfp mice (2 × 106 CD8α+ DCs per mouse). (B) WT but not DNGR-1–deficient CD8α+ DCs cross-present VACV-derived antigens. After 7 days, splenocytes were extracted and restimulated with B8R or A3L VACV peptides. Production of IFN-γ is shown as individual data from a representative experiment (n = 7 biological replicates) of 3 independent experiments performed. (C and D) Cross-presentation of VACV antigens by WT but not DNGR-1–deficient CD8α+ DCs results in CTL killing activity against vaccinia epitopes in vivo. On day 6 after transfer, splenocytes from syngeneic mice were loaded with the early peptide B8R, the late peptide A3L, or no peptide and labeled as in Figure 4 and transferred i.v. Splenocytes were analyzed 16 hours later for specific killing of targets. (C) Representative histogram set. DCs transferred without preincubation with RAW-VACV-UV show the proportion of transferred targets. (D) Percentage specific killing shown as individual data from a representative experiment (n = 4 biological replicates) of 3 performed. #P < 0.001, unpaired 2-tailed Student’s t test.
DNGR-1 deficiency impairs the CD8+ T cell effector response to cross-presented VACV antigens. To test whether DNGR-1 contributes to the CTL response in the context of live virus infection, we injected the WR VACV strain i.d. into the ears of WT and DNGR-1–deficient mice. After 7 days, we restimulated cells from the infected ears ex vivo with WT DCs and VACV antigens to determine the frequency of effector T cells in skin (Figure 6A). As a source of antigen for restimulations, we used RAW-VACV or RAW-VACV-UV cells (see above) and assessed IFN-γ production separately in CD8+ and CD4+ T cells. Interestingly, when RAW-VACV cells were used, CD4+ and CD8+ T cell responses were equivalent in WT and DNGR-1–deficient mice (Figure 6, B and C). In contrast, restimulation with RAW-VACV-UV cells, which permits MHC class I presentation only via the cross-presentation route, revealed a partial blockade of the VACV-specific CD8+ T cell response in the absence of DNGR-1, while the CD4+ T cell response was unaffected (Figure 6, B and C). Thus, only the CD8+ T cell effector response to antigens cross-presented from WR VACV was partially impaired in DNGR-1–deficient mice.
DNGR-1 deficiency impairs the CD8+ T cell effector response to vaccinia virus infection. WT or DNGR-1–deficient mice were infected i.d. in the ear with WR (A) or ΔB13R (D) VACV strains. On day 7 p.i., ear dermal cell suspensions containing effector T cells were restimulated for IFN-γ production in the presence of WT Flt3L BMDCs pretreated with RAW-VACV or RAW-VACV-UV cells. The effector response of CD8+ T cells (B and E) but not CD4+ T cells (C and F) to cross-presented antigens from WR (B and C) or ΔB13R (E and F) VACV is reduced in the absence of DNGR-1. Upper panels show representative dot plot sets. Lower panels show individual data for production of IFN-γ in CD8+ T cells and CD4+ T cells from a representative experiment (n = 4 biological replicates) of 3 performed. *P < 0.05, **P < 0.01, unpaired 2-tailed Student’s t test.
We next tested the ΔB13R VACV strain, which lacks an inhibitor of apoptosis (30). Dermal cells were obtained from WT or DNGR-1–deficient mouse ears infected with ΔB13R VACV for 7 days and restimulated as above (Figure 6D). In contrast to infection with the parental WR strain, the virus-specific CD8+ T cell response to ΔB13R VACV was significantly impaired in DNGR-1–deficient mice, whether assessed by restimulation with RAW-VACV or RAW-VACV-UV (Figure 6E). As with the WR strain, the CD4+ T cell response against ΔB13R VACV was normal in the absence of DNGR-1 (Figure 6F). Moreover, the antibody response against WR or ΔB13R VACV was also identical in WT and DNGR-1–deficient mice (Supplemental Figure 3, A and B). In sum, DNGR-1 deficiency selectively decreased the CD8+ T cell effector response to VACV antigens that rely on cross-presentation.
Loss of DNGR-1 reduces the CD8+ T cell effector response and killing activity in vivo against VACV epitopes. To further test the effect of DNGR-1 deficiency on the effector CD8+ T cell response, we infected WT or DNGR-1–deficient mice i.d. with the WR or ΔB13R VACV strain and measured IFN-γ production by skin T cells 7 days later after ex vivo restimulation with B8R and A3L peptides (Figure 7A). In mice infected with WR, the CD8+ T cell response to the early epitope B8R was not significantly affected, whereas the response to the late epitope A3L was reduced by DNGR-1 deficiency (Figure 7B). This correlates with the fact that VACV antigens from early promoters can be directly presented, whereas direct presentation does not occur for antigens driven by late promoters (32). In contrast, responses to both epitopes were impaired by DNGR-1 deficiency in mice infected with the ΔB13R VACV strain, in line with the greater dependence of this strain on cross-presentation (Figure 7C).
The CD8+ T cell effector response to vaccinia epitopes is decreased in the absence of DNGR-1. (A–C) Absence of DNGR-1 impairs the CD8+ T cell effector response to early and late vaccinia peptides. (A) WT or DNGR-1–deficient mice were infected i.d. in the ear with WR (B) or ΔB13R (C) VACV strains, and 7 days later, ear dermal cell suspensions were obtained and restimulated with B8R and A3L VACV peptides. Upper panels show representative dot plot sets. Lower panels show individual data for production of IFN-γ from a representative experiment (n = 4 biological replicates) of 3 performed. (D–F) CTL killing activity in vivo against vaccinia epitopes is reduced in DNGR-1–deficient mice. (D) WT or DNGR-1–deficient mice were infected with WR (E) or ΔB13R (F) VACV i.d. in the ear, and killing assays were conducted on day 6 as in Figure 4. Upper panels show representative histogram sets. Control histograms from non-infected mice to show the proportion of transferred targets. Lower panels show the percentage specific killing in a representative experiment of 3 performed is shown. Data are presented as mean ± SEM (n = 4 biological replicates). *P < 0.05, **P < 0.01, unpaired 2-tailed Student’s t test.
To determine systemic CTL activity in vivo, we injected syngeneic splenocyte targets loaded with B8R, A3L, or no peptide and labeled as before into mice on day 6 after primary i.d. challenge with the WR or ΔB13R VACV strains (Figure 7D). The results of analysis of killing activity in vivo after 16 hours mirrored those of ex vivo restimulation, with DNGR-1 deficiency having little effect on CTL activity against the early peptide but decreasing killing activity against targets loaded with the late peptide in animals challenged with WR VACV (Figure 7, E and F). The DNGR-1–dependent killing activity against both peptides was greater in the case of infection with the ΔB13R VACV strain, consistent with the ex vivo restimulation assay. Thus, DNGR-1 deficiency impairs overall CTL activity against VACV.
Loss of DNGR-1 delays the resolution of primary infection by vaccinia strains. We tested whether the deficiency in the CD8+ T cell response to VACV antigens in the absence of DNGR-1 affected the control of the lesion caused by the virus. WR and ΔB13R VACV strains were injected i.d. into the ears of WT or DNGR-1 KO mice, and the size of the lesion was monitored over 22 days. Primary expansion of the virus is controlled by innate immunity, and the virus load peaks at days 4–5, when adaptive immunity begins to take over (36). The adaptive immune response initiates lesion resolution by day 8–10, and healing is complete by 3–4 weeks. Notably, DNGR-1 deficiency did not affect WR VACV lesions during the innate phase (up to day 8) but significantly affected subsequent resolution (Figure 8A). Similar effects were seen with the ΔB13R VACV strain, which induced larger and more persistent lesions (Figure 8B), as reported previously (37). DNGR-1 thus plays a non-redundant role in the resolution of infection by two distinct VACV strains.
Loss of DNGR-1 delays the resolution of primary infection by vaccinia strains. WT or DNGR-1–deficient mice were infected i.d. in the ear with WR (A and C) or ΔB13R (B and D) VACV strains. (A and B) DNGR-1–deficient mice show increased lesion size and a delay in the resolution of primary infection. Upper panels show representative pictures at day 15. Lower panels show the temporal development of lesion size (mean ± SEM; n = 12) from a representative experiment of 3 performed. (C and D) Primary infection in the absence of DNGR-1 results in higher viral load during the resolution phase. Viral load in the ears on days 7 and 16 is shown as individual data and the mean from a representative experiment of 3 performed. *P < 0.05, **P < 0.01, #P < 0.001, unpaired 2-tailed Student’s t test.
To monitor the effect of the adaptive response on viral replication, we measured viral titers in the ears on day 7, at the onset of the primary adaptive response, and on day 16, well into the resolution phase. Lack of DNGR-1 did not affect viral titers on day 7 (Figure 8, C and D), showing that DNGR-1 does not impact the early innate response to the virus. However, the viral load in the ears of mice infected with either the WR or the ΔB13R VACV strain increased more than 10-fold in the absence of DNGR-1 by day 16 (Figure 8, C and D). Lack of DNGR-1 thus strongly impairs the control of virus load and lesion resolution, likely through its effects on the CD8+ T cell effector response.
DNGR-1 deficiency impairs the secondary response following vaccination with MVA. To extrapolate these findings to a vaccination setting, we first investigated whether the response to the MVA vaccine was also dependent on DNGR-1. The response of CD8+ T cells, but not CD4+ T cells, was decreased in MVA-immunized DNGR-1–deficient mice, whether measured by restimulation with RAW-VACV, RAW-VACV-UV, or the B8R- and A3L-specific peptides (Figure 9, A and B, and data not shown). As expected, the use of Clec9agfp/gfp BMDCs further impaired restimulation by RAW-VACV or RAW-VACV-UV cells (Supplemental Figure 4). Furthermore, DNGR-1 deficiency also impaired in vivo killing activity against targets pulsed with B8R or A3L peptides (Figure 9C). In fact, DNGR-1 appeared to contribute more significantly to immunity against MVA than to the other replicative VACV strains (compare Figure 9 with Figures 6 and 7).
DNGR-1 deficiency impairs the effector response induced by MVA virus strain. WT or DNGR-1–deficient mice were infected with the MVA VACV strain. The CD8+ T cell effector response to MVA VACV is impaired in the absence of DNGR-1. On day 7 p.i., ear dermal cell suspensions containing effector T cells were restimulated for IFN-γ production in the presence of (A) WT Flt3L BMDCs pretreated with RAW-VACV or RAW-VACV-UV cells or (B) B8R or A3L peptides. Left panels show representative dot plot sets. Right panels show individual data for production of IFN-γ in CD8+ T cells from a representative experiment (n = 4 biological replicates) of 3 performed. (C) CTL killing activity in vivo against vaccinia epitopes is reduced in DNGR-1–deficient mice. WT or DNGR-1–deficient mice were infected i.d. in the ear with MVA VACV, and killing assays were conducted on day 6 as in Figure 4. Data show percentage specific killing as mean ± SEM for a representative experiment (n = 4 biological replicates) of 3 performed. **P < 0.01, #P < 0.001, unpaired 2-tailed Student’s t test.
To address the role of DNGR-1 in the generation of memory responses against VACV, a relevant issue for vaccination with poxviruses, we vaccinated WT or DNGR-1–deficient mice with the MVA VACV strain by s.s. of the base of the tail (31) (Figure 10A). After 21 days, mice were injected i.d. in the ears with the WR VACV strain, and lesion size, effector T cell response, and viral titers were measured. During a secondary response, virus load can be controlled from the outset by the adaptive immune response. Consistent with this notion, viral titers at day 5 after ear injection were significantly lower in vaccinated mice compared with non-vaccinated mice used as controls (Figure 10B). Remarkably, DNGR-1 deficiency resulted in a 10-fold higher viral titer in vaccinated mice, suggesting a defective secondary CTL response. To confirm this, we obtained CD8+ T cells from draining LNs on day 5 after challenge and tested them for their response to B8R and A3L VACV epitopes in the ex vivo restimulation assay. Cells from vaccinated and subsequently challenged DNGR-1–KO mice displayed a markedly weaker secondary response to the vaccinia peptides (Figure 10C). The reduced CD8+ T cell effector response and higher viral titers also manifested themselves in increased lesion size in DNGR-1–deficient mice (Figure 10D). These results show that DNGR-1 is crucial for the generation of an effective memory CTL response following vaccination with an attenuated VACV vaccine strain.
DNGR-1 deficiency blocks the secondary effector response after vaccination with the MVA virus strain. (A) WT or DNGR-1–deficient mice were infected with MVA VACV and challenged 21 days later with the WR VACV strain. (B) DNGR-1 deficiency results in a higher viral load during secondary challenge following vaccination. Viral load in the ears on day 5 after secondary challenge is shown as individual data and the mean in a representative experiment of 3 performed. (C) The CD8+ T cell secondary response to early and late vaccinia peptides is defective in DNGR-1–deficient mice. Cell suspensions obtained from draining LNs on day 7 were tested against B8R and A3L VACV peptides, and the response was analyzed and depicted as in Figure 5. Results are shown from a representative experiment of 3. (D) DNGR-1 deficiency increases the lesion size upon secondary VACV challenge following MVA vaccination. Left panels show representative images at day 10 after secondary challenge. Right panel shows the temporal development of lesion size (mean ± SEM; n = 14) from a representative experiment of 3 performed. *P < 0.05, **P < 0.01, #P < 0.001, unpaired 2-tailed Student’s t test.
Syk deficiency in CD11c+ cells impairs the CD8+ T cell effector response to VACV infection. DNGR-1 signals via the kinase Syk (22, 24), and we therefore examined the contribution of Syk to the capacity of DCs to cross-present antigens from VACV-infected cells (Figure 11A). Comparison of the cross-presentation capacity of Flt3L BMDCs from WT and CD11c-Cre × Sykfl/fl mice (38) revealed that Syk deficiency in DCs impaired the CD8+ T cell response to VACV antigens that were cross-presented but not to those that were directly presented (Figure 11, B and C).
Syk deficiency in CD11c+ cells impairs the CD8+ T cell effector response to VACV infection. (A–C) CD11c-Cre × Sykbfl/fl DCs show deficient cross-presentation of vaccinia antigens from infected cells. (A) Flt3L BMDCs from WT or CD11c-Cre × Sykbfl/fl mice were exposed to RAW-UV, RAW-VACV, or RAW-VACV-UV as in Figure 1. IFN-γ production was measured in CD8+ T effector cells in response to lymphoid cells of WT mice i.d. injected with WR VACV. (B) Representative set of dot plots. (C) Production of IFN-γ (mean ± SEM) from a representative experiment (n = 3 biological replicates) of 3 performed. (D–F) Lack of Syk in CD11c+ cells impairs the CD8+ T cell effector response to early and late vaccinia peptides. (D) WT or CD11c-Cre × Sykbfl/fl mice were infected i.d. in the ear with WR VACV, and 7 days later, ear dermal cell suspensions were obtained and restimulated with B8R and A3L VACV peptides. (E) Representative dot plot set. (F) Production of IFN-γ is shown as individual data from a representative experiment (n = 4 biological replicates) of 3 performed. *P < 0.05, **P < 0.01, unpaired 2-tailed Student’s t test.
To test the influence of Syk on the CD8+ T cell effector response in vivo, we injected WT or CD11c-Cre × Sykfl/fl mice i.d. with WR VACV, and dermal cells obtained after 7 days were restimulated with B8R and A3L VACV peptides (Figure 11, D–F). Syk deficiency in CD11c+ cells in vivo impaired the CD8+ T cell effector response against VACV peptides, suggesting that activation of Syk kinase is a non-redundant step in the signaling pathway downstream of DNGR-1 that regulates cross-presentation of antigens from VACV-infected cells.
Inhibitors of lysosomal activity restore the cross-presentation ability of DNGR-1–deficient DCs. Since DNGR-1 is located in non-lysosomal compartments (24), we hypothesized that DNGR-1 might retain the cargo from VACV-infected cells in a pre-lysosomal compartment with limited proteolytic activity, thereby favoring cross-presentation of antigens (39–41) (Figure 12A). To test this hypothesis, we examined the effects of inhibitors of lysosomal protease activity (leupeptin plus pepstatin) and of lysosome acidification (bafilomycin A1) (41). These drugs did not significantly affect the cross-presentation ability of WT Flt3L BMDCs assayed as in Figure 1 (Figure 12B. However, both treatments restored the cross-presentation capacity of DNGR-1–deficient DCs to levels similar to those of WT DCs (Figure 12B). Direct presentation was not affected by either treatment (Figure 12C). We also tested a proteasome inhibitor (MG-132), which blocked cross-presentation by WT DCs and did not affect the already inhibited cross-presentation by DNGR-1 deficient DCs, indicating that the cross-presentation pathway in this setting was proteasome dependent (data not shown). These results suggest that DNGR-1 might promote the retention of viral cargo in a prelysosomal compartment with low proteolytic activity, thereby permitting antigen cross-presentation.
Inhibitors of lysosomal activity restore the cross-presentation ability of DNGR-1–deficient DCs. (A) Flt3L BMDCs from WT or Clec9agfp/gfp mice were left untreated or treated with bafilomycin A1 (Baf-A1) or leupeptin plus pepstatin (Leu/Pep). To analyze direct presentation or cross-presentation, the DCs were then cocultured for 2 hours with RAW-VACV (B) or RAW-VACV-UV (C) as in Figure 1. As a readout of the restimulation ability of the DCs, IFN-γ production was measured in polyclonal CD8+ T cells specific to VACV antigens, as in Figure 1. Production of IFN-γ is shown as mean ± SEM from a representative experiment (n = 3 biological replicates) of 3 experiments performed. Both Baf-A1 and Leu/Pep restore cross-presentation ability to Clec9agfp/gfp DCs. **P < 0.01, unpaired 2-tailed Student’s t test.